Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis

Tau-PET imaging in Parkinson's disease: a systematic review and meta-analysis

BackgroundPathological tau accumulates in the cerebral cortex of Parkinson's disease (PD), resulting in cognitive deterioration. Positron emission tomography (PET) can be used for in vivo imaging of tau protein. Therefore, we conducted a systematic review and meta-analysis of tau protein burden...

Full description

Bibliographic Details
Main Authors:	Junjiao Zhang, Jianing Jin, Dongning Su, Tao Feng, Huiqing Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Neurology
Subjects:	Parkinson's disease cognitive impairment neurodegenerative diseases tau PET meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1145939/full

Similar Items

Based on Tau PET Radiomics Analysis for the Classification of Alzheimer’s Disease and Mild Cognitive Impairment
by: Fangyang Jiao, et al.
Published: (2023-02-01)

FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01)

Associations between quantitative [18F]flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum
by: Tessa Timmers, et al.
Published: (2019-07-01)

Differential role of CSF alpha-synuclein species, tau and Aβ42 in Parkinson’s Disease
by: Lucilla eParnetti, et al.
Published: (2014-03-01)

Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease
by: Edmond Teng, et al.
Published: (2021-12-01)

Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment
by: Nidhi S. Mundada, et al.
Published: (2023-09-01)

Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis
by: Leian Chen, et al.
Published: (2022-07-01)

Tau oligomers
by: Naruhiko eSahara, et al.
Published: (2014-01-01)

Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
by: Rik Ossenkoppele, et al.
Published: (2021-08-01)

PET Imaging of Tau Pathology: Towards an affirmative diagnosis of Alzheimer’s and Tauopathies
by: Olga eJames, et al.
Published: (2015-03-01)

Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
by: Davina Biel, et al.
Published: (2022-11-01)

Elevated medial temporal lobe and pervasive brain tau‐PET signal in normal participants
by: Val J. Lowe, et al.
Published: (2018-01-01)

Higher serum Lp-PLA2 is associated with cognitive impairment in Parkinson’s disease patients
by: Zubo Wu, et al.
Published: (2024-03-01)

Deep learning detection of informative features in tau PET for Alzheimer’s disease classification
by: Taeho Jo, et al.
Published: (2020-12-01)

Differences in Striatal Metabolism in [<sup>18</sup>F]FDG PET in Parkinson’s Disease and Atypical Parkinsonism
by: Alexander P. Seiffert, et al.
Published: (2022-12-01)

Propagation of Tau via Extracellular Vesicles
by: Mar Pérez, et al.
Published: (2019-07-01)

Multimodal comparisons of QSM and PET in neurodegeneration and aging
by: Petrice M. Cogswell, et al.
Published: (2023-06-01)

Ablation of tau causes an olfactory deficit in a murine model of Parkinson’s disease
by: Leah C. Beauchamp, et al.
Published: (2018-07-01)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
by: Lauren E. McCollum, et al.
Published: (2021-01-01)

Head injury is associated with tau deposition on PET in MCI and AD patients
by: Shannon L. Risacher, et al.
Published: (2021-01-01)

Tau Pathology in Parkinson's Disease
by: Xue Zhang, et al.
Published: (2018-10-01)

Imaging pathological tau in atypical parkinsonisms: A review
by: Anastassia M. Mena, et al.
Published: (2022-01-01)

Utility of Blood-Based Tau Biomarkers for Mild Cognitive Impairment and Alzheimer’s Disease: Systematic Review and Meta-Analysis
by: Alex Zabala-Findlay, et al.
Published: (2023-04-01)

The Metamorphic Nature of the Tau Protein: Dynamic Flexibility Comes at a Cost
by: Jonathan J Sabbagh, et al.
Published: (2016-01-01)

A Tangled Web - Tau and Sporadic Parkinson's Disease
by: Selina Wray, et al.
Published: (2010-12-01)

Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects—a MissionAD tau sub-study
by: Santiago Bullich, et al.
Published: (2022-07-01)

In vivo network models identify sex differences in the spread of tau pathology across the brain
by: Sepideh Shokouhi, et al.
Published: (2020-01-01)

P-tau231 as a diagnostic biomarker for Alzheimer's Disease and mild cognitive impairment: A systematic review and meta-analysis
by: Fardin Nabizadeh, et al.
Published: (2022-01-01)

Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases
by: Susanna Schraen-Maschke, et al.
Published: (2004-04-01)

Tau Protein Biosensors in the Diagnosis of Neurodegenerative Diseases
by: Jafar Sadeghzadeh, et al.
Published: (2023-07-01)

Optimizing quantification of MK6240 tau PET in unimpaired older adults
by: Theresa M. Harrison, et al.
Published: (2023-01-01)

Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals
by: Davina Biel, et al.
Published: (2021-08-01)

Normalization of CSF pTau measurement by Aβ40 improves its performance as a biomarker of Alzheimer’s disease
by: Tengfei Guo, et al.
Published: (2020-08-01)

Phosphorylation of Tau and α-Synuclein Induced Neurodegeneration in MPTP Mouse Model of Parkinson’s Disease
by: Hu S, et al.
Published: (2020-03-01)

Preliminary results of the cohort study of cognitive impairment associated with Parkinson's disease
by: Lilia Rotaru
Published: (2021-09-01)

Network Diffusion Modeling Explains Longitudinal Tau PET Data
by: Amelie Schäfer, et al.
Published: (2020-12-01)

Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines
by: Masaru Tanaka, et al.
Published: (2020-03-01)

The relationship of insulin resistance and diabetes to tau PET SUVR in middle-aged to older adults
by: Gilda E. Ennis, et al.
Published: (2023-03-01)

Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
by: Tracy R. Melzer, et al.
Published: (2019-04-01)

Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-𝜷 in mild cognitive impairment but not in Alzheimer’s disease
by: Feng Xing, et al.
Published: (2021-06-01)